Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

Clinical oncology (Royal College of Radiologists (Great Britain)) - 1 Sept 2007

Zhang G-C, Lin J-Y, Wang Z, Zhou Q, Xu C-R, Zhu J-Q, Wang K, Yang X-N, Chen G, Yang J-J, Huang Y-J, Liao R-Q, Wu Y-L

Abstract excerpt

AIMS: It has been shown that the introduction of a second mutation into the already mutated epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) will alter the sensitivity to tyrosine kinase inhibitors (TKIs). EGFR double activating mutations involving both exons 19 and 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Asian People
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 17537621
DOI: 10.1016/j.clon.2007.04.006

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17537621-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.PMID 17537621Read ↗

[Epithelial growth factor receptor (EGFR) exon double-sequencing analysis in NSClC].Semantic proximity Read ↗

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsSemantic proximity Read ↗

Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy.Semantic proximity Read ↗

Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patientsSemantic proximity Read ↗

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutationsSemantic proximity Read ↗

Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsSemantic proximity Read ↗

[Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].Semantic proximity Read ↗

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.Semantic proximity Read ↗

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.